Recent News

FDA Grants Priority Review to Ruxolitinib for Acute Graft-Versus-Host-Disease

ASTRO 2018: Impact of Dosage on Re-irradiation Rates in Multiple Myeloma

FDA Approves Immunotherapy Combination in Relapsed or Refractory Multiple Myeloma

Rare Case of CML After Stem Cell Transplantation in Patient With Multiple Myeloma

Phase I Study of New Triplet Therapy for Resistant Myeloma

FDA Offers Draft Guidance on Use of MRD in Hematologic Malignancies

Investigational Therapy for Myeloma, STRO-001, Granted Orphan Drug Designation by FDA

ESMO 2018: Strategy for Offsetting Lenalidomide-Induced Rash in Multiple Myeloma

FDA Grants Priority Review to Selinexor for Pentarefractory Multiple Myeloma

Can Simple Blood Tests Diagnose Early Multiple Myeloma?

FDA Permits Use of Next-Generation Sequencing–Based Test in Multiple Myeloma

Quality Care Symposium: Steady Improvement in Survival in Multiple Myeloma

FDA Approves Once-Weekly Carfilzomib With Dexamethasone in Resistant Multiple Myeloma

Novel Approach to Restoring Beneficial Gut Bacteria After HCT

Can Artificial Intelligence Platform Optimize Combination Therapy for Multiple Myeloma?

High-Risk Subset of Newly Diagnosed Multiple Myeloma Identified

Is Resilience a Protective Factor in Disease Trajectory of Multiple Myeloma?

Former MLB Sluggers Team up to Create Awareness of Multiple Myeloma

Monoclonal Antibodies in Multiple Myeloma: Focus on Infusion-Related Reactions

ALL After Multiple Myeloma: Clonally Related or Not?

FDA Accepts Supplemental Biologics License Application for Triplet Myeloma Therapy

Accuracy of Blood Versus Urine Assays in Diagnosis of Multiple Myeloma

Potential of bb2121 CAR T-Cell Therapy in Resistant Multiple Myeloma

UAB Leads Recruitment for Novel Clinical Trial in Multiple Myeloma

Phase III ADMYRE Trial: Plitidepsin + Dexamethasone in Resistant Myeloma

FDA Issues Warning About Long-Term Use of Azithromycin After Donor Stem Cell Transplant

Pembrolizumab in Combination Therapy for Resistant Multiple Myeloma

FDA Grants Orphan Drug Designation to Human Antibody for Treatment of Multiple Myeloma

FDA Grants Fast Track Designation to Galinpepimut-S for Treatment of Myeloma

Preliminary Safety Results of Triplet Therapy for Multiple Myeloma Reported

Stand Up To Cancer Launches Dream Team to Detect Precursor Conditions of Myeloma

Clinical Trials Testing Daratumumab With Checkpoint Inhibitors in Multiple Myeloma Halted

EHA 2018: Addition of Elotuzumab to Pomalidomide and Dexamethasone in Resistant Myeloma

FDA Takes Closer Look at Use of Pembrolizumab in Multiple Myeloma

EHA 2018: Selinexor and Bortezomib Combination in Resistant Multiple Myeloma

EHA 2018: First-in-Class Selinexor in Combination Therapy for Resistant Multiple Myeloma

ASCO 2018: Novel Drug Combination Active in Relapsed Myeloma

ASCO 2018: New Phase III Data on Ibrutinib Plus Rituximab for Waldenström’s Macroglobulinemia

ASCO 2018: Halted Study Reveals Risks of Pembrolizumab Treatment in Multiple Myeloma

ASCO 2018: Once-Weekly Carfilzomib Dosing in Relapsed/Refractory Multiple Myeloma

ASCO 2018: OPTIMISMM Trial Results of Pomalidomide Triplet in Resistant Myeloma

Cancer Vaccine Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma

Novel Chip-Based Blood Assay for Isolation of Circulating Plasma Cells in Myeloma